|
|
Prepublished online as a Blood First Edition Paper on March 20, 2003; DOI 10.1182/blood-2002-09-2768.
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2003, Vol. 102, No. 1, pp. 394-403
TRANSPLANTATION
Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation
Denise A. Wells,
Martin Benesch,
Michael R. Loken,
Carlos Vallejo,
David Myerson,
Wendy M. Leisenring, and
H. Joachim Deeg
From Hematologics, Inc, the Fred Hutchinson Cancer Research Center, and the University of Washington, Seattle.
Marrow cells of myeloid lineage from 115 patients with myelodysplastic syndrome (MDS) were characterized by multidimensional flow cytometry and compared with findings in 104 patients with various disorders and 25 healthy donors. Based on phenotypic and scatter characteristics, a flow cytometric scoring system (FCSS) was developed that allowed for a simple numerical display of results. The flow cytometric scores were categorized as normal/mild (0-1), moderate (2-3), or severe ( 4). Most flow cytometric abnormalities were significantly (P < .05) more frequent in patients with MDS than in the control cohort. Flow cytometric scores in MDS patients were then retrospectively compared with marrow blast counts assessed by morphology, cytogenetics, hematologic parameters, and International Prognostic Scoring System (IPSS) risk categorization. The flow cytometric scores correlated inversely with leukocyte and absolute neutrophil counts (P < .01) and correlated directly with IPSS scores (P < .01) and with IPSS cytogenetic risk categories (P < .01). In 111 MDS patients who underwent allogeneic hematopoietic stem cell transplantation, flow scores correlated with posttransplantation outcome. The probabilities of posttransplantation relapse were 3%, 15%, and 33% for patients with mild, moderate, and severe FCSS scores, respectively (P < .01), and overall survival was 74%, 40%, and 36%, respectively, for the 3 groups (P < .01). In multivariate analyses, there was a significant contribution of the flow score independent of the IPSS in predicting survival and relapse (P < .01, P = .02, and P = .03, respectively). These data suggest that FCSS is useful in assessing marrows for diagnosis of MDS and in determining the prognostic outcome in patients with this disorder. (Blood. 2003;102:394-403)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Goardon, E. Nikolousis, A. Sternberg, W.-K. Chu, C. Craddock, P. Richardson, R. Benson, M. Drayson, G. Standen, P. Vyas, et al.
Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes
Haematologica,
August 1, 2009;
94(8):
1160 - 1163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. van de Loosdrecht, C. Alhan, M. C. Bene, M. G. Della Porta, A. M. Drager, J. Feuillard, P. Font, U. Germing, D. Haase, C. H. Homburg, et al.
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
Haematologica,
August 1, 2009;
94(8):
1124 - 1134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ogata, M. G. Della Porta, L. Malcovati, C. Picone, N. Yokose, A. Matsuda, T. Yamashita, H. Tamura, J. Tsukada, and K. Dan
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study
Haematologica,
August 1, 2009;
94(8):
1066 - 1074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Wang, O. Pozdnyakova, J. L. Jorgensen, L. J. Medeiros, D. Stachurski, M. Anderson, A. Raza, and B. A. Woda
Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats
Haematologica,
January 1, 2009;
94(1):
29 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Scott, D. A. Wells, M. R. Loken, D. Myerson, W. M. Leisenring, and H. J. Deeg
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome
Blood,
October 1, 2008;
112(7):
2681 - 2686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. E. Craig and K. A. Foon
Flow cytometric immunophenotyping for hematologic neoplasms
Blood,
April 15, 2008;
111(8):
3941 - 3967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. van de Loosdrecht, T. M. Westers, A. H. Westra, A. M. Drager, V. H. J. van der Velden, and G. J. Ossenkoppele
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
Blood,
February 1, 2008;
111(3):
1067 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Chang, B. E. Storer, B. L. Scott, E. M. Bryant, H. M. Shulman, M. E. Flowers, B. M. Sandmaier, R. P. Witherspoon, R. A. Nash, J. E. Sanders, et al.
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
Blood,
August 15, 2007;
110(4):
1379 - 1387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ogata, Y. Kishikawa, C. Satoh, H. Tamura, K. Dan, and A. Hayashi
Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes
Blood,
August 1, 2006;
108(3):
1037 - 1044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. K. Zehentner, W. Fritschle, T. Stelzer, K. M. Ghirardelli, K. Hunter, C. Wentzel, R. Bennington, C. L. Hansen, D. Myerson, M. Kalnoski, et al.
Minimal Disease Detection and Confirmation in Hematologic Malignancies: Combining Cell Sorting with Clonality Profiling
Clin. Chem.,
March 1, 2006;
52(3):
430 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and J. M. Bennett
The Myelodysplastic Syndromes: Diagnosis and Treatment
Mayo Clin. Proc.,
January 1, 2006;
81(1):
104 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. B. Kerbauy, V. Lesnikov, N. Abbasi, S. Seal, B. Scott, and H. J. Deeg
NF-{kappa}B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
Blood,
December 1, 2005;
106(12):
3917 - 3925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
